
Introducing
AT-004
We are changing lives by transforming the treatment of inflammatory skin diseases
AT-004 is a topical solution being engineered to revolutionize the treatment of multiple skin disorders, starting with our lead indication, acne vulgaris—a long-term inflammatory condition affecting over 600 million people globally. By leveraging an innovative acetylcholinesterase inhibitory mechanism, AT-004 is designed to target the root cause of inflammation in the skin. Our research into this unique mechanism, could inform treatment across a wide range of skin disorders beyond acne vulgaris — including atopic dermatitis, psoriasis and rosacea.

More than skin deep
Acne is a persistent skin condition primarily triggered by the accumulation of dead skin cells and excess oil within hair follicles, which often become breeding grounds for skin bacteria. The hallmark signs of acne include the appearance of blackheads or whiteheads, the emergence of pimples, an oily skin texture, and in some cases, scarring. The condition is often linked to genetic factors, though external triggers like cosmetics, food allergies, poor cell turnover, and underlying health issues also play substantial roles.
The impact of acne transcends skin-deep concerns, posing significant psychological challenges including increased anxiety, depression, and diminished self-esteem. It’s imperative to address not only the cosmetic aspect but the comprehensive adversities associated with acne. AT-004, our pioneering topical solution, targets the inflammatory roots of acne and other skin disorders, aiming to revolutionize skin treatment, restore self-esteem, and significantly mitigate the holistic burden carried by individuals affected by such conditions.

Research links acne vulgaris to:

Underlying these is a loss of self-esteem.



Findings published in the International Journal of Women’s Dermatology vol 4 issue 1 in March
2018, authored by dermatologists S.M. Gallitano MD and D.S Berson MtD